NWRN — Newron Pharmaceuticals SpA Share Price
0.000.00%
Last trade - 00:00- CH₣143.28m
- CH₣178.12m
- €9.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 16.26 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -128.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 7.04 | 5.26 | 5.76 | 6.09 | 9.06 | 21.94 | 22.39 | 17.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Directors
- Ulrich Kostlin CHM
- Stefan Weber CEO
- Roberto Galli VFN
- Dennis Dionne VPR (70)
- Marco Caremi VBD
- Ravi Anand OTH
- Luca Benatti NED (60)
- Donald De Bethizy NED
- Robert Holland NED (63)
- Patrick Langlois NID (75)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 17th, 2002
- Public Since
- December 12th, 2006
- No. of Employees
- 23
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 18,631,834
- Address
- via Antonio Meucci 3, BRESSO, 20091
- Web
- https://www.newron.com/
- Phone
- +39 026103461
- Auditors
- Ernst & Young SpA
Upcoming Events for NWRN
Newron Pharmaceuticals SpA Annual Shareholders Meeting
Half Year 2024 Newron Pharmaceuticals SpA Earnings Release
Similar to NWRN
Cosmo Pharmaceuticals NV
SIX Swiss Exchange
Dottikon Es Holding AG
SIX Swiss Exchange
Galenica AG
SIX Swiss Exchange
Novartis AG
SIX Swiss Exchange
PolyPeptide AG
SIX Swiss Exchange
FAQ
What is the Newron Pharmaceuticals SpA share price?
As of Today at 19:25 UTC, shares in Newron Pharmaceuticals SpA are trading at CH₣7.69. This share price information is delayed by 15 minutes.
How has the Newron Pharmaceuticals SpA share price performed this year?
Shares in Newron Pharmaceuticals SpA last closed at CH₣7.69 and the price had moved by +67.17% over the past 365 days. In terms of relative price strength the Newron Pharmaceuticals SpA share price has outperformed the FTSE Global All Cap Index by +54.2% over the past year.
What are the analyst and broker recommendations for Newron Pharmaceuticals SpA?
The overall consensus recommendation for Newron Pharmaceuticals SpA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Newron Pharmaceuticals SpA dividend yield?
Newron Pharmaceuticals SpA does not currently pay a dividend.
Does Newron Pharmaceuticals SpA pay a dividend?
Newron Pharmaceuticals SpA does not currently pay a dividend.
When does Newron Pharmaceuticals SpA next pay dividends?
Newron Pharmaceuticals SpA does not currently pay a dividend.
How do I buy Newron Pharmaceuticals SpA shares?
To buy shares in Newron Pharmaceuticals SpA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Newron Pharmaceuticals SpA?
As of the previous close price of CH₣7.69, shares in Newron Pharmaceuticals SpA had a market capitalisation of CH₣143.28m.
Where are Newron Pharmaceuticals SpA shares listed?
Here are the trading details for Newron Pharmaceuticals SpA:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: NWRN
What kind of share is Newron Pharmaceuticals SpA?
Based on an overall assessment of its quality, value and momentum Newron Pharmaceuticals SpA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Newron Pharmaceuticals SpA share price forecast for 2024?
The analyst consensus target price for shares in Newron Pharmaceuticals SpA is CH₣10.70. That is 39.13% above the last closing price of CH₣7.69.
Analysts covering Newron Pharmaceuticals SpA currently have a consensus Earnings Per Share (EPS) forecast of -€0.00 for the next financial year.
What is the trend in the Newron Pharmaceuticals SpA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Newron Pharmaceuticals SpA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +28.16%.
As of the last closing price of CH₣7.69, shares in Newron Pharmaceuticals SpA were trading +23.68% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Newron Pharmaceuticals SpA PE Ratio?
The Newron Pharmaceuticals SpA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣7.69.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Newron Pharmaceuticals SpA?
Newron Pharmaceuticals SpA's management team is headed by:
- Ulrich Kostlin - CHM
- Stefan Weber - CEO
- Roberto Galli - VFN
- Dennis Dionne - VPR
- Marco Caremi - VBD
- Ravi Anand - OTH
- Luca Benatti - NED
- Donald De Bethizy - NED
- Robert Holland - NED
- Patrick Langlois - NID